REGENXBIO Inc.

NasdaqGS:RGNX Stock Report

Market Cap: US$521.2m

REGENXBIO Management

Management criteria checks 2/4

REGENXBIO's CEO is Curran Simpson, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $4.78M, comprised of 11.9% salary and 88.1% bonuses, including company stock and options. directly owns 0.072% of the company’s shares, worth $376.16K. The average tenure of the management team and the board of directors is 6.8 years and 7.9 years respectively.

Key information

Curran Simpson

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage11.9%
CEO tenureless than a year
CEO ownership0.07%
Management average tenure6.8yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth

May 01
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth

Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?

Apr 24
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
author-image

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

Mar 30 Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.

5 Reasons To Buy Regenxbio Right Now

Mar 26

The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%

Mar 04
The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

CEO Compensation Analysis

How has Curran Simpson's remuneration changed compared to REGENXBIO's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$5mUS$572k

-US$227m

Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$241m

Mar 31 2024n/an/a

-US$260m

Dec 31 2023US$3mUS$513k

-US$263m

Sep 30 2023n/an/a

-US$261m

Jun 30 2023n/an/a

-US$274m

Mar 31 2023n/an/a

-US$270m

Dec 31 2022US$2mUS$475k

-US$280m

Sep 30 2022n/an/a

US$74m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$101m

Dec 31 2021US$3mUS$448k

US$128m

Sep 30 2021n/an/a

-US$212m

Jun 30 2021n/an/a

-US$145m

Mar 31 2021n/an/a

-US$121m

Dec 31 2020US$2mUS$428k

-US$111m

Sep 30 2020n/an/a

-US$91m

Jun 30 2020n/an/a

-US$135m

Mar 31 2020n/an/a

-US$103m

Dec 31 2019US$2mUS$382k

-US$95m

Sep 30 2019n/an/a

-US$64m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$371k

US$100m

Compensation vs Market: Curran's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD2.71M).

Compensation vs Earnings: Curran's compensation has increased whilst the company is unprofitable.

CEO

Curran Simpson (62 yo)

less than a year

Tenure

US$4,784,544

Compensation

Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...

Leadership Team

NamePositionTenureCompensationOwnership
Curran Simpson
Presidentless than a yearUS$4.78m0.072%
$ 376.2k
Mitchell Chan
Executive VP & CFOless than a yearUS$3.21mno data
Olivier Danos
Executive VP & Chief Scientific Officer8.2yrsUS$2.96m0.12%
$ 607.0k
Patrick Christmas
Executive VP & Chief Strategy and Legal Officer8.8yrsUS$2.74m0.10%
$ 539.5k
Stephen Pakola
Executive VP & Chief Medical Officer6.1yrsUS$2.70m0.062%
$ 323.2k
Craig Malzahn
Executive Vice Presidentno datano data0.016%
$ 81.5k
Shiva Fritsch
Chief Communications & People Officer7.6yrsno datano data
Ram Palanki
Executive VP of Commercial Strategy & Operations6.8yrsno datano data

6.8yrs

Average Tenure

54yo

Average Age

Experienced Management: RGNX's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Curran Simpson
Presidentless than a yearUS$4.78m0.072%
$ 376.2k
David Stump
Independent Director9.6yrsUS$339.98k0.013%
$ 67.5k
George Migausky
Independent Director3.7yrsUS$339.98k0.013%
$ 67.5k
Argeris Karabelas
Independent Director10yrsUS$339.98k0.013%
$ 67.5k
Inder Verma
Member of Scientific Advisorno datano datano data
Allan Fox
Director16.3yrsUS$337.48k11.52%
$ 60.0m
Judith Swain
Member of Scientific Advisorno datano datano data
Alexandra Glucksmann
Independent Director7yrsUS$327.48k0.013%
$ 67.5k
Daniel Tassé
Lead Independent Director8.8yrsUS$347.48k0.013%
$ 67.5k
Jean Bennett
Independent Director3.7yrsUS$324.98k0.013%
$ 67.5k
Kenneth Mills
Chairman16.2yrsUS$5.84m0.78%
$ 4.1m
Jennifer Zachary
Independent Director2.9yrsUS$329.98k0.015%
$ 78.0k

7.9yrs

Average Tenure

69.5yo

Average Age

Experienced Board: RGNX's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 12:40
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

REGENXBIO Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Alec StranahanBofA Global Research